2ème semestre 2025

Publication 2ème sem 2025

Détails
Clics : 326

Bonjour à tous,
Vous trouverez ci-dessous les titres des publications des membres du réseau ENDOCAN TUTHYREF.
Félicitations aux auteurs!

Retrouvez les publications dans :   Espace membre

2ème sem 2025

  1. Ansart F, de Ponthaud C, Buffet C, Menegaux F, Gaujoux S, Chereau N. One- or Two-Step Total Thyroidectomy for Cancer Indications: A 20-Year Retrospective Study from a Referral Center. Ann Surg Oncol. 2025 Apr;32(4):2329-2334. doi: 1245/s10434-024-16707-6. Epub 2024 Dec 29. PMID: 39739263. Voir fichier : Ansart2025-Total-Thyroidectomy.pdf

  2. Berrandou TE, Cordina-Duverger E, Mulot C, Guizard AV, Schvartz C, Laurent- Puig P, Zidane M, De Vathaire F, Guénel P, Truong T. Polymorphisms in circadian rhythm genes and the risk of differentiated thyroid cancer. Front Genet. 2025 Jun 4;16:1539090. doi: 10.3389/fgene.2025.1539090. PMID: 40534841; PMCID: Voir fichier : Berrandou2025- Polymorphisms.pdf

  3. Bischoff H, Fattori A, Moinard-Butot F, Schneegans O, Diaz P, Reita D, Rimelen V, Voegeli AC, Bender L. First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib. Thyroid. 2025 Jun;35(6):701-705. doi: 10.1089/thy.2025.0017. Epub 2025 May 16. PMID: 40376737. Voir fichier : Bischoff2025-ALK-Fusion.pdf

  4. Do Cao C, Godbert Y, Bardet S, Borson-Chazot F, Decaussin-Petrucci M, Wassermann J, Lugat A, Nascimento C, Leboulleux S, Narciso B, Jannin A, Hadoux J, Schwartz P, Hescot S, Buffet C, Lamartina L; ENDOCAN-TUTHYREF network. ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular- derived thyroid cancer. Ann Endocrinol (Paris). 2025 Jul;86(4):101735. doi: 1016/j.ando.2025.101735. Epub 2025 May 7. PMID: 40345488. Voir fichier : DoCao2025-Refractory-follicular.pdf

  5. Garnier S, Mahéo C, Potard G, Cavarec MB, Roudaut N, Thuillier P, Marianowski R, Abgral R, Leclere JC. Contribution of 18 F-fluorocholine PET-CT to the preoperative localisation of parathyroid adenoma for the treatment of primary Sci Rep. 2025 Mar 23;15(1):10018. doi: 10.1038/s41598-025-94735-2. PMID: 40122914; PMCID: PMC11930921. Voir fichier : Garnier2025- Contribution-of-18F.pdf

  6. Haissaguerre M, Groussin L, Lamartina L, Buffet C, Caron P. Key data from the 2024 European Thyroid Association annual meeting: Differentiated thyroid What's new in low-risk thyroid carcinoma? Update after the 2024 ETA congress. Ann Endocrinol (Paris). 2025 Apr;86(2):101707. doi: 10.1016/j.ando.2025.101707. Epub 2025 Feb 3. PMID: 39909103. Voir fichier : Haissaguerre2025- Differentiated-thyroid-carcinoma.pdf

  7. Hartl DM, Bani MA, Ghuzlan AA, Simonescu AE, Breuskin I, Marhic A, Albiges L, Lamartina L, Hadoux J. Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy. Front Oncol. 2025 May 28;15:1543060. doi: 10.3389/fonc.2025.1543060. PMID: 40502628; PMCID: Voir fichier : Hartl2025-Locally-invasive.pdf

  8. Jannin A, Escande A, Hartl D, Louvel G, Breuskin I, Borson-Chazot F, Hadoux J, Lamartina L, Do Cao C, Deschamps F. ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and/or metastatic thyroid cancer. Ann Endocrinol (Paris). 2025 Jul;86(4):101790. doi: 10.1016/j.ando.2025.101790. Epub 2025 May PMID: 40379205. Voir fichier : Jannin2025-Locoregionaltherapies.pdf

  9. Lamartina L, Hadoux J, Borson-Chazot F, Do Cao C. ENDOCAN TUTHYREF network consensus recommendations for refractory thyroid cancer management. Ann Endocrinol (Paris). 2025 Jul;86(4):101732. doi: 10.1016/j.ando.2025.101732. Epub 2025 Apr 25. PMID: 40288438. Voir fichier : Lamartina2025-refractory-thyroid.pdf

  10. Lamartina L, Jannin A, Decaussin-Petrucci M, Bardet S, Escande A, Ciappuccini R, Borson Chazot F, Al Ghuzlan A, Do Cao C, Hadoux J. ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer. Ann Endocrinol (Paris). 2025 Jul;86(4):101788. doi: 10.1016/j.ando.2025.101788. Epub 2025 May 9. PMID: 40350149. Voir fichier : Lamartina2025-Anaplastic-thyroid.pdf

  11. Lasolle H, Do Cao C, Lamartina L, Al Ghuzlan A, Drui D, Buffet C, Leboulleux S, Hescot S, Godbert Y, Zerdoud S, Ciappuccini R, Jannin A, Hadoux J, Borson- Chazot F. ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer. Ann Endocrinol (Paris). 2025 Jul;86(4):101733. doi: 1016/j.ando.2025.101733. Epub 2025 Apr 25. PMID: 40288439. Voir fichier : Lasolle2025-Refractory-medullary.pdf

  12. Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder M, Spitzweg C, Worden FP, Wirth L, Ho A. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025 Jun;13(6):516-527. doi: 10.1016/S2213-8587(25)00064-6. Epub 2025 Apr 30. PMID: Voir fichier : Leboulleux2025-Redifferentiation.pdf

  13. Luzuy-Guarnero V, Jarlborg P, Demarchi MS, Mavromati M, De Vito C, Saiji E, Bianchetto Wolf N, Leboulleux S, Triponez F. Prise en charge du cancer thyroïdien de souche folliculaire en 2025 [Management of follicular cell-derived thyroid cancer in 2025]. Rev Med Suisse. 2025 Jun 11;21(922):1210-1215. French. doi: 10.53738/REVMED.2025.21.922.47328. PMID: 40509717. Voir fichier : Luzuy-Guarnero2025-souche-folliculaire.pdf

  14. Roy M, Ghander C, Bigorgne C, Brière M, Deniziaut G, Ansart F, Lussey- Lepoutre C, Buffet C. An update on management of cytologically indeterminate thyroid nodules. Ann Endocrinol (Paris). 2025 Apr;86(2):101711. doi: 1016/j.ando.2025.101711. Epub 2025 Feb 15. PMID: 39961482. Voir fichier : roy2025- cytologically.pdf

  15. Ryška A, Capdevila J, Dettmer MS, Elisei R, Führer D, Hadoux J, Jarzab B, Locati LD, Newbold K, Tallini G, Uccella S, Wirth L, Singh R, Simon IM, Camacho P, Fugazzola L. Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus. Eur Thyroid J. 2025 Jun 18:ETJ-25-0024. doi: 1530/ETJ-25-0024. Epub ahead of print. PMID: 40540622. Voir fichier : Ryska2025-molecular.pdf

  16. Schubert L, Haissaguerre M, Caron P, Groussin L. Key data from the 2024 European Thyroid Association annual congress: What's new in aggressive thyroid carcinoma? Ann Endocrinol (Paris). 2025 Jul;86(4):101734. doi: 1016/j.ando.2025.101734. Epub 2025 May 6. PMID: 40409200. Voir fichier : Schubert2025-aggressive-thyroid.pdf

Publication 3ème trim 2025

Détails
Clics : 111

Bonjour à tous,
Vous trouverez ci-dessous les titres des publications des membres du réseau ENDOCAN TUTHYREF.
Félicitations aux auteurs!

Retrouvez les publications dans :   Espace membre

3ème trim 2025

  1. Bailey GE, Azadi J, Russell JO, Cochand-Priollet B, Maleki Z. Ultrasound- guided thyroid fine-needle aspiration and concurrent core needle biopsy: A comparative study with practical clinical scenarios. Am J Clin Pathol. 2025 Sep 9;164(3):500-512. doi: 10.1093/ajcp/aqaf079. PMID: 40713932. Bailey-Ultrasound-guided_thyroid2025.pdf

  2. Beddok A, Baptiste Morvan J, Boudin L, Da Silva Ribeiro Mota A, Dutheil P, Guilbert P, Rozenblum L, Theresette Guilbert A, Zalzali M, Marcy PY, Thariat J. The role of external beam radiation therapy in thyroid cancer management: A Scoping Review. Int J Radiat Oncol Biol Phys. 2025 Sep 26:S0360-3016(25)06313-8. doi: 10.1016/j.ijrobp.2025.09.050. Epub ahead of print. PMID: 41016492. Voir fichier : Beddok-The_role_of_external_beam2025.pdf

  3. Ciappuccini R, Saguet-Rysanek V, Bompain PA, Balosso J, Leman R, Castera L, Bardet S. NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer: a report of two cases. Eur Thyroid J. 2025 Oct 6;14(5):e250100. doi: 10.1530/ETJ-25-0100. PMID: 40990092; PMCID: PMC12508307. Voir fichier : Ciappuccini- NSD32025

  4. Do Cao C, Desailloud R, Topolinski H, Crépin M, Flament C, Leteurtre E, Cardot-Bauters C, Frénois F, Ait-Yahya É, Bonte F, Leclerc J, Pigny P. Analysis of genetic predisposition to familial non-medullary thyroid cancer by whole genome sequencing. Ann Endocrinol (Paris). 2025 Sep 10;86(5):102456. doi: 10.1016/j.ando.2025.102456. Epub ahead of print. PMID: 40939960. Voir fichier : DoCao-Analysis_of_genetic2025.pdf

  5. Elisei R, Wirth LJ, Capdevila J, Hoff AO, Tahara M, Sherman EJ, Hu MI, Ge MH, Wadsley J, Vaisman F, Kopeckova K, Krajewska J, Olvera D, Churchill C, Maeda P, Gilligan AM, Lin Y, Payakachat N, Robinson B, Hadoux J, Brose MS. Patient- Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid Cancer. Thyroid. 2025 Aug 18. doi: 10.1177/10507256251367352. Epub ahead of print. PMID: 40828665. Voir fichier : Elisei-Patient-Reported2025.pdf

  6. Gauduchon T, Varnier R, Cassier PA. Selpercatinib in the treatment of thyroid cancer. Future Oncol. 2025 Aug;21(20):2585-2592. doi: 10.1080/14796694.2025.2531575. Epub 2025 Jul 10. PMID: 40638871; PMCID: PMC12344793. Voir fichier : pdf

  7. Klein M, Klein AJC, Raem AM, Garrelfs N, Fischer HJ, Hölzle F, Wermker K. Next-Generation Sequencing Reveals the Potential Role of RET Protooncogene in Metastasis Progression in Medullary Thyroid Cancer. Curr Issues Mol Biol. 2025 Jul 18;47(7):560. doi: 10.3390/cimb47070560. PMID: 40729029; PMCID: PMC12293786. Voir fichier : Klein-Next-Generation2025.pdf

  8. Nappi C, Cras Y, Lamartina L, Deandreis D. Dosimetry in Advanced Thyroid Cancer: A Piece of a Puzzle? Endocrinol Metab Clin North Am. 2025 Sep;54(3):407-418. doi: 10.1016/j.ecl.2025.03.011. Epub 2025 Apr 28. PMID: 40716895. Voir fichier : Nappi-Dosimetry2025.pdf

  9. Porcelli T, De Stefano MA, Luongo C, Schlumberger M, Salvatore D. The unique signature of tyrosine kinase inhibitor-induced hypothyroidism. Lancet Diabetes Endocrinol. 2025 Sep;13(9):803-812. doi: 10.1016/S2213-8587(25)00193-7. Epub 2025 Jul 14. PMID: 40675173. Voir fichier : Porcelli-The_unique_signature2025.pdf

  10. Puygrenier P, Deniziaut G, Gaujoux S, Vinh JYKD, Buffet C, Menegaux F, Chereau N. Comparison of Oncocytic and Follicular Carcinoma of the Thyroid Without Initial Distant Metastasis. World J Surg. 2025 Sep;49(9):2449-2456. doi: 10.1002/wjs.70018. Epub 2025 Jul 25. PMID: 40714958; PMCID: PMC12435605. Voir fichier : Puygrenier-Comparison_of_Oncocytic2025.pdf

  11. Sajous C, Lasolle H, Decaussin-Petrucci M, Lopez J, Borson Chazot F. Prolonged response to lenvatinib in a poorly differentiated thyroid carcinoma with leptomeningeal carcinomatosis. Ann Endocrinol (Paris). 2025 Sep 10;86(5):102458. doi: 10.1016/j.ando.2025.102458. Epub ahead of print. PMID: 40939961. Voir fichier : Sajou-Prolonged_response2025.pdf

  12. Taprogge J, Murray I, Sharman H, Gape P, Leek F, Abreu C, Vávrová L, Newbold K, Wong KH, Luster M, Verburg FA, Schurrat T, Vija L, Courbon F, Vallot D, Bardiès M, Schumann S, Eberlein U, Lassmann M, Flux G. Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer. Eur Thyroid J. 2025 Jul 1;14(4):e250097. doi: 10.1530/ETJ-25-0097. PMID: 40532046; PMCID: PMC12229276. Voir fichier : Taprogge-Predictive_factors2025.pdf
  13.